Kazakhstan aims to register homegrown cancer drug by end of 2025Kazakhstan’s Minister of Science and Higher Education, Sayasat Nurbek, has announced that a domestically developed cancer drug is on track for registration by the end of 2025.Currently in Phase II clinical trials, the drug has demonstrated promising results, including an average tumor reduction of 30% and remission in some patients. Initially tested for colon cancer, the drug is now being evaluated for its effectiveness against other types of cancer.“We plan to register this drug by the end of this year and enter the market,” Nurbek stated during a government briefing.The Minister also emphasized efforts to expedite the drug’s development, aiming to bring it to market faster than the typical 10-year clinical trial cycle. “We have streamlined procedures to accelerate the process, and we look forward to sharing more good news soon,” he added.The development of Kazakhstan’s anti-cancer drug gained widespread attention in January 2024 when Prime Minister Olzhas Bektenov visited Nazarbayev University. By July of the same year, the second phase of testing had already begun, involving approximately 3,000 participants in Astana, Almaty, and Pavlodar. (ICE ALMATY)

Fonte notizia: INTERFAX